Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2017 | The role of pharmacists when introducing biosimilar monoclonal antibodies into practice

Simon Cheesman • 7 Oct 2017
BOPA 2017
General Antibodies Rituximab

During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm, MRPharmS from the University College London Hospital, London, UK, describes the role of pharmacists when introducing biosimilars into clinical practice based on his experience of biosimilar rituximab.

This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.

More from Simon Cheesman

2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman • 12 Oct 2018
0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
1:16
Practical intricacies surrounding biosimilar adoption
Simon Cheesman • 6 Oct 2017
1:12
An audit of infusion-related reactions with biosimilar rituximab in London
Simon Cheesman • 6 Oct 2017

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals